238 related articles for article (PubMed ID: 28461107)
1. Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats.
Gertel S; Mahagna H; Karmon G; Watad A; Amital H
Clin Immunol; 2017 Nov; 184():77-81. PubMed ID: 28461107
[TBL] [Abstract][Full Text] [Related]
2. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Tanaka Y; Maeshima K; Yamaoka K
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
[TBL] [Abstract][Full Text] [Related]
4. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Kubo S; Yamaoka K; Kondo M; Yamagata K; Zhao J; Iwata S; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2192-8. PubMed ID: 24013646
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis.
Almanzar G; Kienle F; Schmalzing M; Maas A; Tony HP; Prelog M
Rheumatology (Oxford); 2019 Nov; 58(11):2051-2060. PubMed ID: 31106368
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
Ibrahim SSA; Salama MA; Selima E; Shehata RR
Life Sci; 2020 Nov; 260():118261. PubMed ID: 32795539
[TBL] [Abstract][Full Text] [Related]
7. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.
Maeshima K; Yamaoka K; Kubo S; Nakano K; Iwata S; Saito K; Ohishi M; Miyahara H; Tanaka S; Ishii K; Yoshimatsu H; Tanaka Y
Arthritis Rheum; 2012 Jun; 64(6):1790-8. PubMed ID: 22147632
[TBL] [Abstract][Full Text] [Related]
8. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
LaBranche TP; Jesson MI; Radi ZA; Storer CE; Guzova JA; Bonar SL; Thompson JM; Happa FA; Stewart ZS; Zhan Y; Bollinger CS; Bansal PN; Wellen JW; Wilkie DP; Bailey SA; Symanowicz PT; Hegen M; Head RD; Kishore N; Mbalaviele G; Meyer DM
Arthritis Rheum; 2012 Nov; 64(11):3531-42. PubMed ID: 22899318
[TBL] [Abstract][Full Text] [Related]
9. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Tanaka Y; Yamaoka K
Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice.
Nishimura K; Saegusa J; Matsuki F; Akashi K; Kageyama G; Morinobu A
Arthritis Rheumatol; 2015 Apr; 67(4):893-902. PubMed ID: 25545152
[TBL] [Abstract][Full Text] [Related]
11. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
12. [Inhibitory effect and mechanism of tofacitinib on the secretion of cytokines by T cells in human peripheral blood].
Wu K; Zhao J; Wu Q; Wu C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Nov; 33(11):1448-1455. PubMed ID: 29268845
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells.
Bing SJ; Lyu C; Xu B; Wandu WS; Hinshaw SJ; Furumoto Y; Caspi RR; Gadina M; Gery I
Mol Vis; 2020; 26():641-651. PubMed ID: 33088168
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Hodge JA; Kawabata TT; Krishnaswami S; Clark JD; Telliez JB; Dowty ME; Menon S; Lamba M; Zwillich S
Clin Exp Rheumatol; 2016; 34(2):318-28. PubMed ID: 26966791
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
16. The Janus kinase inhibitor tofacitinib inhibits TNF-α-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes.
Kawaguchi Y; Waguri-Nagaya Y; Tatematsu N; Oguri Y; Kobayashi M; Nozaki M; Asai K; Aoyama M; Otsuka T
Clin Exp Rheumatol; 2018; 36(4):559-567. PubMed ID: 29352846
[TBL] [Abstract][Full Text] [Related]
17. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
Sonomoto K; Yamaoka K; Kubo S; Hirata S; Fukuyo S; Maeshima K; Suzuki K; Saito K; Tanaka Y
Rheumatology (Oxford); 2014 May; 53(5):914-8. PubMed ID: 24441153
[TBL] [Abstract][Full Text] [Related]
18. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
Tanaka Y
J Biochem; 2015 Sep; 158(3):173-9. PubMed ID: 26152731
[TBL] [Abstract][Full Text] [Related]
19. Kirenol exerts a potent anti-arthritic effect in collagen-induced arthritis by modifying the T cells balance.
Lu Y; Xiao J; Wu ZW; Wang ZM; Hu J; Fu HZ; Chen YY; Qian RQ
Phytomedicine; 2012 Jul; 19(10):882-9. PubMed ID: 22673798
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS.
Calama E; Ramis I; Domènech A; Carreño C; De Alba J; Prats N; Miralpeix M
Pulm Pharmacol Ther; 2017 Apr; 43():60-67. PubMed ID: 28087469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
